-
IDO1 Inhibition and Tumor-Protective JAK2/STAT3
2026-09-17
This study shows that pharmacological IDO1 inhibition can produce a paradoxical tumor-protective response: immune cells become more active, yet myeloid-derived IL-6 stimulates tumor-intrinsic JAK2/STAT3 signaling. Single-cell RNA sequencing in a syngeneic CT26 model provides a rationale for combining IDO1 blockade with inhibitors of the IL-6/JAK2/STAT3 axis.
-
AZD1480: Turning JAK2/STAT3 Escape Into Insight
2026-09-17
A translational framework for using AZD1480, an ATP-competitive JAK2 inhibitor, to dissect tumor-intrinsic STAT3 survival programs, validate adaptive resistance mechanisms, and strengthen combination study design.
-
BMS 309403 Workflows for FABP4 Research
2026-09-16
BMS 309403 provides a selective, reversible way to interrogate FABP4 in macrophage inflammation, lipid handling, and foam-cell biology. This workflow guide connects cell-based dose finding with the SERCA2–calcineurin–FoxO1–FABP4 axis relevant to atherosclerosis and metabolic disease research.
-
CLK2–BRCA1 Signaling in Platinum-Resistant Ovarian Cancer
2026-09-16
The reference study identifies Cdc2-like kinase 2 (CLK2) as a clinically associated and functionally active driver of platinum resistance in ovarian cancer. Its central mechanistic finding is that CLK2 phosphorylates BRCA1 at Ser1423 to enhance DNA damage repair, while platinum-associated p38 signaling stabilizes CLK2, suggesting a stress-adaptive resistance pathway that can be tested in cell and xenograft models.
-
AMPK–SQSTM1 Feedback Under Metabolic Stress
2026-09-15
The 2024 Autophagy study identifies a double-positive feedback loop in which SQSTM1/p62 and AMPK reinforce one another during metabolic stress, jointly activating NRF2-dependent antioxidant defense. Its mechanistic framework connects lysosomal deacidification, TFEB/TFE3 regulation, ROS-dependent TAK1 signaling, and cancer-cell adaptation, while suggesting experimentally testable points for disrupting stress tolerance.
-
Clathrin-Mediated Entry of Type III Grass Carp Reovirus
2026-09-15
Wang et al. used pharmacological inhibition, transmission electron microscopy, and RT-qPCR to show that genotype III grass carp reovirus enters CIK cells through a dynamin-dependent, clathrin-mediated pathway that requires endosomal acidification. The study also found that nocodazole-sensitive microtubule disruption did not significantly block entry, helping distinguish endocytic requirements from broader cytoskeletal effects.
-
Chloroquine Diphosphate: Autophagy Workflows
2026-09-14
Build more interpretable autophagy assay, chemotherapy sensitization, and lysosome-function experiments with a water-soluble research reagent. This guide connects concentration planning and flux-aware controls with a recent JEV lysosome study, while clearly separating validated findings from practical starting conditions.
-
Myriocin: SPT Inhibition in Lipid Research
2026-09-14
Myriocin enables controlled suppression of de novo sphingolipid synthesis for mechanistic studies spanning ceramide biology, cancer research, and immunology. This workflow-focused guide shows how to pair pharmacological SPT inhibition with lipid, viability, apoptosis, and cell-cycle readouts for more interpretable experiments.
-
Berberine, RXRα/PPARγ, and SASP in Atherosclerosis
2026-09-13
The 2025 reference study identifies an RXRα/PPARγ/NEDD4 pathway through which berberine suppresses senescence-associated secretory phenotype inflammation in macrophage-derived foam cells and atherosclerotic plaques. Its combination of Smart-seq analysis, foam-cell experiments, plaque phenotyping, and macrophage-specific RXRα knockdown provides a mechanistic framework for studying nuclear-receptor control of vascular inflammation.
-
Sodium salicylate in Stromal Stress Assays
2026-09-12
Sodium salicylate is an NF-κB inhibitor suited to inflammation and oxidative-stress studies. This article explains how to use it as a time-resolved pathway probe while interpreting the sequential stromal-remodeling strategy reported in pancreatic cancer nanomedicine.
-
PD 0332991: Designing Rb-Resolved Assays
2026-09-11
PD 0332991 and Palbociclib HCl provide a powerful way to connect CDK4/6 inhibition with Rb-dependent cell-cycle biology. This guide develops an assay-centered framework that separates cytostasis, pathway context, formulation, and inflammatory signaling from simple viability measurements.
-
HDAC6 Tubulin Lactylation and Microtubule Dynamics
2026-09-11
The reference study identifies α-tubulin K40 lactylation as a metabolism-sensitive post-translational modification that increases microtubule dynamics in neurons. It further establishes HDAC6 as a principal lactylation writer, linking intracellular lactate to cytoskeletal remodeling, neurite outgrowth, and branching.
-
Eltanexor (KPT-8602) Workflow for XPO1 Studies
2026-09-10
Build a practical Eltanexor workflow that connects XPO1 inhibition with nuclear-retention, viability, Wnt/β-catenin, and COX-2 readouts. The approach spans hematologic models and colorectal cancer organoids while separating published evidence from assay-development recommendations.
-
HLY78: Wnt/β-Catenin Pathway Modulator Guide
2026-09-10
HLY78 provides ligand-dependent potentiation of Wnt/β-catenin signaling through the Axin-LRP6 interface, making it useful for mechanism-focused cell, zebrafish, and developmental assays. This guide translates that mechanism into practical workflows while distinguishing established evidence from exploratory fibrosis applications.
-
AZD1480 and the Tumor-Protective JAK2/STAT3 Axis
2026-09-09
Tumor-directed immune activation can produce compensatory survival signaling inside cancer cells. This thought-leadership analysis positions AZD1480 as a mechanistic JAK2 inhibitor for testing IL-6–JAK2/STAT3 adaptation, refining biomarker strategy, and designing translational combination studies.